Get started
Author

Olaf‐Oliver Wolz

Observed names: Olaf-Oliver Wolz, Olaf‑Oliver Wolz, Wolz, O.
Institution: CureVac (Germany)
ORCID: 0000-0002-3140-7204
Observed ORCID: 0000-0002-3140-7204
OpenAlex ID: A5000149275
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial
2021 · Peter G. Kremsner, Philipp Mann, et al. · Wiener klinische Wochenschrift · 204
PDF
Human NACHT, LRR, and PYD domain–containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase
2017 · Xiao Liu, Tica Pichulik, et al. · Journal of Allergy and Clinical Immunology · 139
PDF
B-cell–specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice
2016 · Gero Knittel, Paul Liedgens, et al. · Blood · 137
PDF
The fungal ligand chitin directly binds TLR2 and triggers inflammation dependent on oligomer size
2018 · Katharina Fuchs, Yamel Cardona Gloria, et al. · EMBO Reports · 120
PDF
BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity
2021 · Zsófia Agnes Bittner, Xiao Liu, et al. · The Journal of Experimental Medicine · 86
Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization
2014 · Monika Avbelj, Olaf-Oliver Wolz, et al. · Blood · 74
PDF
HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization
2018 · Christophe Boudesco, Els Verhoeyen, et al. · Blood · 46
Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities
2018 · Alexander N. R. Weber, Yamel Cardona Gloria, et al. · Cancer Immunology Immunotherapy · 35
HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy
2016 · Annika Nelde, Juliane Sarah Walz, et al. · OncoImmunology · 33
PDF
A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance
2015 · Hui Wang, Souhayla El Maadidi, et al. · Hepatology · 24
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study
2022 · Xavier Sáez-Llorens, Claudio Lanata, et al. · Vaccine X · 21
Absence of Non-Canonical, Inhibitory MYD88 Splice Variants in B Cell Lymphomas Correlates With Sustained NF-κB Signaling
2021 · Yamel Cardona Gloria, Stephan H. Bernhart, et al. · Frontiers in Immunology · 12
PDF
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study
2024 · Brandon J. Essink, Craig Shapiro, et al. · Human Vaccines & Immunotherapeutics · 10
PDF
A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant
2022 · Olaf-Oliver Wolz, Sarah-Katharina Kays, et al. · Vaccines · 9
PDF
Putative link between Polo-like kinases (PLKs) and Toll-like receptor (TLR) signaling in transformed and primary human immune cells
2019 · Souhayla El Maadidi, Alexander N. R. Weber, et al. · Scientific Reports · 7
PDF
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity
2024 · Olaf-Oliver Wolz, Dominik Vahrenhorst, et al. · Vaccines · 3
PDF
Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]
2023 · Xavier Sáez-Llorens, Claudio Lanata, et al. · Vaccine X · 2
Examining Myddosome Formation by Luminescence-Based Mammalian Interactome Mapping (LUMIER)
2017 · Olaf-Oliver Wolz, Manfred Koegl, et al. · Methods in molecular biology · 1
MyD88 mutations in B cell tumors: constitutive signaling by TIR domain oligomerization
2016 · Olaf‐Oliver Wolz · 1
Hsp110 Sustains Myd88-Dependent Nfkb Signaling in Activated B Cell Diffuse Large B Cell Lymphoma
2017 · Boudesco, C., Causse, S., et al. · HAL
Works count: 20
Citation count: 964
H-index: 12
I10-index: 13
Year
Topic
Type